Alnylam Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of innovative therapeutics based on ribonucleic acid interference. The company reported selling, general, and administrative expenses of $1,210,713,000.00 indicating its operational overhead costs. Additionally, the company incurred an interest expense of $252,627,000.00 reflecting its debt servicing obligations. A net loss of $313,747,000.00 was reported, indicating challenges in its operations. With its stock identified by the symbol 'ALNY' in the market, the weighted average number of diluted shares outstanding is 134,684,000.00 reflecting potential dilution effects. Alnylam's pipeline of investigational RNAi therapeutics addresses a range of conditions, including genetic disorders, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Marketed products such as ONPATTRO (patisiran), GIVLAARI, and OXLUMO highlight its commitment to addressing unmet medical needs. Furthermore, the company is advancing multiple candidates in its pipeline, including givosiran and cemdisiran, enhancing its portfolio with potential therapies for various diseases. Strategic collaborations with prominent partners like Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme bolster its development capabilities. The stock is priced at $453.56 positioning it in the higher-end market. It has an average trading volume of 1,343,362.00 indicating moderate liquidity. With a mid-range market capitalization of $41,920,803,754.00 the company is a steady performer in the competitive landscape. It is a key player in the biopharmaceutical industry, contributing significantly to the overall market landscape. Additionally, it belongs to the Healthcare sector, driving innovation and growth within the field. Alnylam continues to enhance its position through collaborations and partnerships, unlocking new avenues for discovering and delivering RNAi therapeutics. The company's focus on cutting-edge science and strategic alliances marks it as a noteworthy entity in advancing healthcare solutions and addressing complex diseases. As it navigates its challenges, Alnylam remains committed to its vision of transforming the treatment landscape through pioneering biopharmaceutical innovations.